Whitehawk Therapeutics (NASDAQ:WHWK) Issues Earnings Results, Misses Estimates By $1.25 EPS

Key Points

• Whitehawk Therapeutics reported a quarterly EPS of ($0.76), missing consensus estimates by $1.25.
• The company's negative return on equity was recorded at 85.57%, paired with a net margin of 99.42%.
• Despite the earnings miss, WHWK stock saw a 1.7% increase during midday trading, reaching $1.75.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of $0.49 by ($1.25), Zacks reports. Whitehawk Therapeutics had a negative return on equity of 75.99% and a net margin of 99.42%.

Whitehawk Therapeutics Trading Up 2.0%

Shares of WHWK stock traded up $0.04 during midday trading on Wednesday, reaching $1.75. 70,061 shares of the company were exchanged, compared to its average volume of 150,830. Whitehawk Therapeutics has a 12 month low of $1.37 and a 12 month high of $3.81. The company has a market capitalization of $82.24 million, a price-to-earnings ratio of -29.08 and a beta of 0.55.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded shares of Whitehawk Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.